B-cell SIGLEC-5 engages T-cell components of the elastin receptor complex (ERC) to suppress inflammatory T-cell cytokines
Piper, C. J. M.; Metcalfe, C.; Layeghi, M.; Montamat-Garcia, G.; Baig, Z.; Ferrier Esposito, A.; Nitschke, L.; Catalan, D.; Mauri, C.
Show abstract
SIGLECs remain poorly defined in human B-cell biology beyond SIGLEC-2/CD22 and SIGLEC-10. Here, we identify a previously unrecognized regulatory pathway involving the paired receptors SIGLEC-5 and SIGLEC-14 at the human B-T-cell interface. We show that activated B-cells differentially regulate these receptors: SIGLEC-5 is predominantly surface-expressed and induced by CD40 engagement, whereas SIGLEC-14 is primarily secreted and upregulated after both CD40 and TLR9 stimulation. We further identify EBP (elastin binding protein) and CTSA (cathepsin A) components of the elastin receptor complex (ERC), expressed by activated T-cells, as a novel ligand for both SIGLEC-5 and SIGLEC-14. Functionally, ERC-associated engagement of SIGLEC-5 on B-cells suppresses T-cell IFN-g; and IL-17 expression, establishing SIGLEC-5 as a B-cell-expressed inhibitory SIGLEC that restrains inflammatory T-cell cytokine responses. SIGLEC-14 does not alter this suppression, as SIGLEC-5+ B-cells from SIGLEC-14-sufficient and -null individuals show comparable inhibitory activity. These findings broaden SIGLEC-mediated adaptive immune regulation, with relevance to inflammatory and autoimmune disease.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.